Naureen Quibria
Stock Analyst at Capital One
(0.19)
# 3,536
Out of 4,479 analysts
12
Total ratings
20%
Success rate
-45.91%
Average return
Main Sectors:
Top Industries:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMMP Immutep | Initiates: Overweight | $10 | $1.88 | +431.91% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $2.32 | +244.83% | 1 | Mar 11, 2024 | |
| CARM Carisma Therapeutics | Initiates: Overweight | $10 | $1.44 | +594.44% | 1 | Oct 3, 2023 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $34.80 | +141.38% | 1 | Aug 16, 2023 | |
| ONCT Oncternal Therapeutics | Downgrades: Hold | n/a | $7.05 | - | 2 | Apr 4, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $13.46 | +197.18% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $6.03 | +82.42% | 1 | Sep 7, 2022 | |
| CMRX Chimerix | Initiates: Overweight | $7 | $0.86 | +711.59% | 2 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $3.09 | +578.73% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | n/a | $0.21 | - | 1 | Oct 14, 2021 |
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $1.88
Upside: +431.91%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $2.32
Upside: +244.83%
Carisma Therapeutics
Oct 3, 2023
Initiates: Overweight
Price Target: $10
Current: $1.44
Upside: +594.44%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $34.80
Upside: +141.38%
Oncternal Therapeutics
Apr 4, 2023
Downgrades: Hold
Price Target: n/a
Current: $7.05
Upside: -
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $13.46
Upside: +197.18%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $6.03
Upside: +82.42%
Chimerix
Sep 7, 2022
Initiates: Overweight
Price Target: $7
Current: $0.86
Upside: +711.59%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $3.09
Upside: +578.73%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: n/a
Current: $0.21
Upside: -